# High SRD5A3 expression is correlated with promotion of proliferation and inhibition of apoptosis in B-cell non-Hodgkin lymphoma and suggests a poor prognosis

## TL;DR

High SRD5A3 expression in B-cell non-Hodgkin lymphoma is linked to faster cancer growth, less cell death, and worse patient survival, suggesting it could be a new target for treatment.

## Contribution

This study identifies SRD5A3 as a novel biomarker and potential therapeutic target in B-cell non-Hodgkin lymphoma via the PI3K-AKT pathway.

## Key findings

- High SRD5A3 expression correlates with poor prognosis in B-NHL patients.
- SRD5A3 promotes B-NHL cell proliferation and inhibits apoptosis.
- SRD5A3 activates the PI3K-AKT signaling pathway to drive oncogenic effects.

## Abstract

Steroid 5α-reductase 3 (SRD5A3) is an important molecule involved in glycosylation and steroid hormone formation and is highly expressed in most tumors. However, The role of SRD5A3 in B-cell non-Hodgkin lymphoma (B-NHL) and its mechanism are unknown.

We used a multi-omics database to explore the expression and prognostic significance of SRD5A3 in various tumors, including B-NHL. We established SRD5A3 high- and low-expression B-NHL cell lines to test the effects of SRD5A3 on cell proliferation and apoptosis in vitro, and to analyze the signaling pathways associated with the effects of SRD5A3 on B-NHL.

We found that SRD5A3 was highly expressed in most tumors, including B-NHL, and was more highly expressed in patients age ≥60 years, high levels of LDH, stage III-IV, non-GCB subtype, and extra-nodal invasion. Survival analysis showed that high SRD5A3 expression predicted poorer overall survival (OS). Further experiments showed that SRD5A3 high expression promoted B-NHL growth and attenuates apoptosis, conversely, SRD5A3 low expression inhibited B-NHL growth and promoted apoptosis. Western blot assay showed SRD5A3 promotes B-NHL cells growth by regulating the PI3K-AKT signaling pathway.

Our findings suggest that SRD5A3 exerts its oncogenic effects by regulating the PI3K-AKT pathway, may serve as a potential biomarker and therapeutic target for B-NHL, providing information for clinical decision-making.